OncoSELECT is a fast, minimally invasive analysis of circulating tumour DNA from a blood sample for lung (NSCLC), colon, breast (ER+ or HER2+) cancer patients.

OncoSELECT is the perfect diagnostic tool to:

- Identify therapeutic solutions for cancer patients not able to get their tumor biopsied
- Monitor the evolution of lung, colorectal and breast cancers
- Detect treatment resistance as soon as it appears

WHY CHOOSING ONCOSELECT?

- To select a therapy: mainly for patients whose tissue sample is not available, when it is challenging or not possible to perform a biopsy of the primary tumour or of any metastasis, or if the biopsy sample is too old.
- As a monitoring tool: it is the right way to monitor the tumour response to the treatment, detect potential resistance, adapt the treatment and doing so, extend the patient’s life. It is fast, minimally invasive for the patient and more sensitive than routine imaging.

WHEN TO PERFORM ONCOSELECT?

According to a recent change in FDA guidelines, liquid biopsy is now approved as the first diagnostic tool for Non-Small Cell Lung Cancer patients. OncoSELECT is the perfect test to make a first screening of the most relevant genes related to treatments. For monitoring purposes, OncoSELECT should ideally be performed in the middle of the treatment and 2 weeks after the last dose has been given. Subsequently, it will depend on the treatment, the cancer type and the anamnesis of the patient. Our suggestion is to perform the follow-up every three months or at the frequency decided by the oncologist.

MATERIAL

1 blood sample (2 Streck tubes of 10 ml each)

CANCER-SPECIFIC LIQUID BIOPSY

Next-generation sequencing

- Analysis of more than 100 mutations of resistance and sensitivity to targeted therapies (SNV, Indel, translocation and CNV)
- Specific genes selected for each cancer type

INTEGRATED THERANOSTIC REPORT

Reporting of new variant(s) associated with resistance and/or new treatment options
WHY IS ONCOSELECT UNIQUE?

OncoSELECT is unique because it is focusing only on the targets that matters specifically for each cancer type, while directing the analysis on the essentials markers for treatment response or resistance.

Currently OncoDNA is offering 3 versions of OncoSELECT for:

1. Lung cancer patients (NSCLC)
2. Colorectal cancer patients (CRC)
3. Breast cancer patients (HR hormone-positive or HER2+ breast cancer types)

HOW LONG DOES IT TAKE TO GET THE RESULTS?

We are committed to sending the report within 7 working days once OncoDNA has received and checked the quality of the liquid biopsy sample and all the required clinical information.

HOW IS THE PROCESS THAT SIMPLE?

1. Blood collection and shipping to OncoDNA (material and DHL airway bill provided by us)
2. Reception and QC check of the sample. Assessment of cancer type and target selection
3. Analysis of the sample and creation of the report
4. After 7 days, the integrative and comprehensive report is ready to be shared with you